Poster Schedule

12:30 PM – 1:30 PM EEST

P-175: Improving Anti-BCMA CAR-T functionality with novel immunomodulatory agent Iberdomide (CC220) in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-176: ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-177: Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM).

12:30 PM – 1:30 PM EEST

P-178: Evolution of the Multiple Myeloma Treatment Landscape in Portugal: a 5-year longitudinal analysis of treatment patterns in nationwide clinical practice

12:30 PM – 1:30 PM EEST

P-179: Altered Lipid Metabolism in IMiD/CELMoD Resistant Multiple Myeloma Confers Novel and Targetable Vulnerabilities

12:30 PM – 1:30 PM EEST

P-180: PYGO2 is upregulated in multiple myeloma patients with 1q21+ : a potential novel therapeutic target.

12:30 PM – 1:30 PM EEST

P-181: Towards an IMiD sensitive C57BL/KaLwRij murine model of multiple myeloma

12:30 PM – 1:30 PM EEST

P-182: Natural killer cells are active against myeloma cells with loss of tumor suppressor genes

12:30 PM – 1:30 PM EEST

P-183: Bottlebrush prodrugs as triplex combination therapies for multiple myeloma

12:30 PM – 1:30 PM EEST

P-184: Lenalidomide: Rash or no rash, that is the question

12:30 PM – 1:30 PM EEST

P-185: Discovery of Novel Proteasome Activators that Enhance Antigen Presentation and Trigger Anti-myeloma T-cell Immunity

12:30 PM – 1:30 PM EEST

P-186: Proteasome Regulatory ATPase PSMC2 Promotes Drug Resistance by Mitigating ER Stress and Portends Reduced Overall Survival in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-187: Therapeutically Targeting 19S Proteasome-associated Subunit PSMD1/Rpn2 in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-188: Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-189: Indirubin Derivative Acts as Dual Inhibitor Targeting Proteasome and Autophagy for Treating Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-190: Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma

12:30 PM – 1:30 PM EEST

P-191: Acquisition of venetoclax resistance is characterized by higher expression of anti-apoptotic regulators, less mitochondrial priming, and broader resistance to anti-MM agents.

12:30 PM – 1:30 PM EEST

P-192: Increased serum CRBN levels are associated with improved survival in MM patients

12:30 PM – 1:30 PM EEST

P-193: Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma and in other plasma cell dyscrasias

12:30 PM – 1:30 PM EEST

P-194: Non-coding RNA LINC01410 interacts with the minichromosome maintenance (MCM) complex and is a dependency in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-195: Loss of GABARAP mediates resistance to immunogenic chemotherapy by altering protein trafficking of calreticulin on the cell surface

12:30 PM – 1:30 PM EEST

P-196: IMPACT OF PREFERENTIAL CODONIC LOSS OF ARGININE IN MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-197: Tissue Factor as a New Target for CAR-NK Cell Immunotherapy of Multiple Myeloma and Triple-Negative Breast Cancer

12:30 PM – 1:30 PM EEST

P-198: Impact of Blocking the CD47 Axis on Phagocytosis of Myeloma Cells Treated with CD38 Antibodies and Proteasome Inhibitors

12:30 PM – 1:30 PM EEST

P-199: Novel Antibodies Identified by Phage Display Induce Direct Myeloma Cell Death

12:30 PM – 1:30 PM EEST

P-200: MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism

12:30 PM – 1:30 PM EEST

P-201: Induction of pyroptosis for the treatment of multiple myeloma

12:30 PM – 1:30 PM EEST

P-202: SLAMF1-derived peptide P7N4-Pen as anti-myeloma treatment

12:30 PM – 1:30 PM EEST

P-203: Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The iinnovate clinical development program

12:30 PM – 1:30 PM EEST

P-204: Targeting TENT5C-associated regulation of antibody synthesis against multiple myeloma.

12:30 PM – 1:30 PM EEST

P-205: Heme promotes venetoclax resistance in multiple myeloma

12:30 PM – 1:30 PM EEST

P-206: 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy

12:30 PM – 1:30 PM EEST

P-207: Targeting iron homeostasis in combination with IMiDs as a therapeutic strategy in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-208: Infectious Risks in Newly Diagnosed Multiple Myeloma (NDMM) patients receiving (or treated with) daratumumab based regimens: a multicentric Italian experience

12:30 PM – 1:30 PM EEST

P-209: Multiple myeloma-derived circulating extracellular vesicles affect normal human stromal cell behaviour and promote tumor progression: a multi-omic approach

12:30 PM – 1:30 PM EEST

P-210: Novel Pro-Survival Role for Tryptophan 2,3 Dioxygenase 2 in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-211: Antiviral treatment improves outcome for individuals with multiple myeloma and other monoclonal gammopathies associated with Hepatitis B or C viruses.

12:30 PM – 1:30 PM EEST

P-212: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-213: COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)

12:30 PM – 1:30 PM EEST

P-214: A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-215: Apurinic/apyrimidinic nuclease 1 (APEX1) can impact multiple related pathways to drive growth and genomic instability in myeloma

12:30 PM – 1:30 PM EEST

P-216: The PBK-FOXM1 axis disrupts the DREAM transcriptional repressor complex, contributing to the growth and genomic instability of myeloma

12:30 PM – 1:30 PM EEST

P-217: ULK3-mediated autophagy is a tractable therapeutic target for the treatment of multiple myeloma.

12:30 PM – 1:30 PM EEST

P-218: TLR-activation may promote drug resistance and disease progression in multiple myeloma

12:30 PM – 1:30 PM EEST

P-219: Investigating the Proteasome Stress Response as a Potential Therapeutic Target in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-220: Discovery of tumor-reactive T cell receptors by functional single cell interaction analyses in patients with newly diagnosed multiple myeloma

12:30 PM – 1:30 PM EEST

P-221: PIM2 kinase regulates TIGIT expression and energy metabolism in NK cells from multiple myeloma patients

12:30 PM – 1:30 PM EEST

P-222: Development of pERp1-ADC as a Novel Therapeutic for Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-223: Pomalidomide (P) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real-World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

12:30 PM – 1:30 PM EEST

P-224: Single-Center Experience of Selinexor-based Combination Therapies for Relapsed Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-225: Uninvolved hypogammaglobulinemia was not a predictor of the infection risk in anti-CD38 chemotherapy

12:30 PM – 1:30 PM EEST

P-226: Safety and clinical activity of belantamab mafodotin combined with carfilzomib, lenalidomide, and dexamethasone after at least one prior line of therapy, interim results from phase 1 clinical trial.

12:30 PM – 1:30 PM EEST

P-227: Safety and clinical activity of ruxolitinib combined with carfilzomib and dexamethasone for patients with carfilzomib-refractory multiple myeloma:Rresults from a phase 1 clinical trial.

12:30 PM – 1:30 PM EEST

P-228: Use of cilta-cel CAR T cells following previous use of a BCMA-directed CAR T-cell product in heavily treated patients with relapsed/refractory multiple myeloma: A single institution case series

12:30 PM – 1:30 PM EEST

P-229: Exposure-Response Analysis of Venetoclax in Combination with Carfilzomib and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients

12:30 PM – 1:30 PM EEST

P-230: Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study

12:30 PM – 1:30 PM EEST

P-231: ABBV-383, a BCMA-CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: A Multicenter, Phase 1b Dose Optimization Study With Step-up Dosing

12:30 PM – 1:30 PM EEST

P-232: Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment

12:30 PM – 1:30 PM EEST

P-233: Physician perspectives regarding conventional marrow testing and MRD assessments to guide decision-making in myeloma

12:30 PM – 1:30 PM EEST

P-234: DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

12:30 PM – 1:30 PM EEST

P-235: Clinical and sociodemographic characterization of multiple myeloma patients with symptomatic relapse and/or refractory disease under treatment in Portugal: an observational, multicenter study

12:30 PM – 1:30 PM EEST

P-236: Cutaneous presentation of multiple myeloma in relapse after AutoPBSCT

12:30 PM – 1:30 PM EEST

P-237: Bendamustine (B) is associated with low response rates in heavily pretreated relapsed refractory multiple myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-238: A Real-World Observational Study of Belantamab Mafodotin (Belamaf) as a Treatment for Relapsed/Refractory Multiple Myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-239: Dynamic Risk Model: A Novel Approach Incorporating Functional High Risk Factors for Predicting Survival Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-240: Efficacy and Safety of Cilta-Cel and T-Cell Phenotype Analyses in Patients With Relapsed/Refractory Multiple Myeloma and Prior Non-Cellular Anti-BCMA Therapy: Phase 2 CARTITUDE-2 Cohort C

12:30 PM – 1:30 PM EEST

P-241: African American Relapsed/Refractory Multiple Myeloma patients have a Progression Free Survival benefit with selinexor treatment in the STORM study

12:30 PM – 1:30 PM EEST

P-242: Real-world treatment patterns and clinical outcomes amongst patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody

12:30 PM – 1:30 PM EEST

P-243: Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil.

12:30 PM – 1:30 PM EEST

P-244: Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison.

12:30 PM – 1:30 PM EEST

P-245: Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-246: Real-world attrition rates after second-line therapy or later in patients from the Flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide

12:30 PM – 1:30 PM EEST

P-247: Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): Analysis of the LINKER-MM1 study

12:30 PM – 1:30 PM EEST

P-248: REAL-WORLD OUTCOMES OF TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS BY TREATMENT EXPERIENCE: THE ASSOCIATION OF PRIOR LINES AND PENTA-REFRACTORINESS WITH PROGRESSION-FREE AND OVERALL SURVIVAL

12:30 PM – 1:30 PM EEST

P-249: THE ASSOCIATION BETWEEN AGE, PERFORMANCE STATUS, FRAILTY AND OUTCOMES IN REAL-WORLD CLINICAL PRACTICE AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-250: THE RELATIONSHIP OF EXTRAMEDULLARY DISEASE AND HIGH-RISK CYTOGENETICS ON REAL-WORLD OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-251: VARIATION IN REAL-WORLD OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA ACROSS CLINICAL SUBGROUPS: A GERMAN REGISTRY ANALYSIS

12:30 PM – 1:30 PM EEST

P-252: Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-253: REAL WORLD DATA OF SAFETY AND EFFICACY PROFILE OF DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: LOW GRADE RESPIRATORY INFECTIONS AND HIGH EFFICACY IN ALL TREATMENT LINES

12:30 PM – 1:30 PM EEST

P-254: Cardiac and hidden toxicity of Carfilzomib in presence of Cardiometabolic Syndrome and Early-Stage Heart Failure with reduced Ejection Fraction.

12:30 PM – 1:30 PM EEST

P-255: Efficacy of a Second Autologous Stem Cell Transplant for Multiple Myeloma and Correlation with Response to Initial Transplant: A Single-Center Experience

12:30 PM – 1:30 PM EEST

P-256: Initial Report of a Single Institution Experience with Teclistamab for Relapsed or Refractory Multiple Myeloma Including Prior BCMA

12:30 PM – 1:30 PM EEST

P-257: Real-world treatment patterns and clinical outcomes among patients with triple-class exposed (TCE) multiple myeloma (MM)

12:30 PM – 1:30 PM EEST

P-258: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

12:30 PM – 1:30 PM EEST

P-259: Targeting Ubiquitin Chains With Cyclic Peptides For The Treatment Of Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-260: Ipilimumab after CD34-Selected Allogeneic Stem Cell Transplantation (Allo HCT) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-261: Comparison of Different Cutoffs of Time from Last Drug Exposure to Disease Progression for Defining Drug Refractoriness in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-262: Retreatment With Previously Refractory Drugs in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-263: Treatment patterns and clinical outcomes in multiple myeloma patients previously treated with lenalidomide and an anti-CD38 monoclonal antibody: findings from the PREAMBLE registry

12:30 PM – 1:30 PM EEST

P-264: A Phase 1b Study of Isatuximab and Bendamustine for Triple-Class Refractory Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-265: Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial

12:30 PM – 1:30 PM EEST

P-266: Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-267: Teclistamab Is Safe and Effective In Relapse Refractory Multiple Myeloma Patients with End Stage Renal Disease: A Case Series

12:30 PM – 1:30 PM EEST

P-268: AN INNOVATIVE INTERACTIVE CASE-BASED ONLINE EDUCATION TOOL SIGNIFICANTLY INCREASES KNOWLEDGE AND COMPETENCE OF CLINICIANS MANAGING TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-269: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE, COMPETENCE AND CONFIDENCE OF PHYSICIANS IN THE MANAGEMENT OF MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-270: EFFECTIVENESSS OF MICRO CME AT IMPROVING CLINICAL KNOWLEDGE AND COMPETENCE RELATED TO BCMA-TARGETED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

12:30 PM – 1:30 PM EEST

P-271: Online CME improves clinical decision-making in the management of patients with relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-272: Belantamab Mafodotin For Relapsed/Refractory Multiple Myeloma: A Real-World Observational Study Update

12:30 PM – 1:30 PM EEST

P-273: Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience

12:30 PM – 1:30 PM EEST

P-274: Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): A pooled analysis from the MagnetisMM studies

12:30 PM – 1:30 PM EEST

P-275: CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-276: Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy

12:30 PM – 1:30 PM EEST

P-277: Venetoclax Versus Bortezomib, in Combination with Daratumumab and Dexamethasone, in Patients With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-278: Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States

12:30 PM – 1:30 PM EEST

P-279: Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Real world Patients with Relapsed/Refractory Multiple Myeloma: KMM2004 study

12:30 PM – 1:30 PM EEST

P-280: A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-281: Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory MM

12:30 PM – 1:30 PM EEST

P-282: Ranking Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma (RRMM): International Physician Panel Consensus following a Systematic Review of the Literature

12:30 PM – 1:30 PM EEST

P-283: Systematic literature review of prognostic factors for relapsed/refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-284: Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)

12:30 PM – 1:30 PM EEST

P-285: Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connect® Multiple Myeloma Disease Registry

12:30 PM – 1:30 PM EEST

P-286: Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: Post-hoc analysis from MagnetisMM-3

12:30 PM – 1:30 PM EEST

P-287: Isatuximab Plus Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma in Real Life Context in France: IMAGE Subgroup Analysis Based on Subgroups of Interest

12:30 PM – 1:30 PM EEST

P-288: A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T treatment

12:30 PM – 1:30 PM EEST

P-289: The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy.

12:30 PM – 1:30 PM EEST

P-290: Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel

12:30 PM – 1:30 PM EEST

P-291: Outcomes of Third-Line Therapy in Multiple Myeloma Patients: a Report from the Canadian Myeloma Research Group (CMRG)

12:30 PM – 1:30 PM EEST

P-292: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

12:30 PM – 1:30 PM EEST

P-293: Real-World Treatment Patterns and Outcomes in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey

12:30 PM – 1:30 PM EEST

P-294: Comparative Effectiveness of Teclistamab vs Real-world Physician’s Choice of Therapy in the LocoMMotion and MoMMent Studies for Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-295: Efficacy, Survival and Safety of Selinexor, Bortezomib and Dexamethasone (SVd) in Patients with Lenalidomide-Refractory Multiple Myeloma: Subgroup Data from the BOSTON Trial

12:30 PM – 1:30 PM EEST

P-296: LIGHTHOUSE: MELFLUFEN, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO AN IMID AND A PROTEASOME INHIBITOR OR WITH ≥3 PRIOR LINES OF THERAPY

12:30 PM – 1:30 PM EEST

P-297: Selinexor, bortezomib, and dexamethasone in patients with previously treated multiple myeloma: updated results of BOSTON trial by prior therapies

12:30 PM – 1:30 PM EEST

P-298: Retrospective study of treatment patterns and clinical outcomes by race in patients with triple-class-exposed multiple myeloma treated in a real-world setting

12:30 PM – 1:30 PM EEST

P-299: Survival Outcomes in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Either IMiD- or Non-IMiD-Based Regimens After Triple-Class Exposure in the PREAMBLE Registry

12:30 PM – 1:30 PM EEST

P-300: Targeting DNMT3B impairs multiple myeloma cell proliferation and clonogenic capacity and enhances sensitivity to standard of care agents.

12:30 PM – 1:30 PM EEST

P-301: Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

12:30 PM – 1:30 PM EEST

P-302: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)—FINAL EFFICACY AND SAFETY RESULTS

12:30 PM – 1:30 PM EEST

P-303: BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE TRIPLE-REFRACTORY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

12:30 PM – 1:30 PM EEST

P-304: TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA: EFICACY OF THE NEW IMMUNOTHERAPIES AND NEW UNMET MEDICAL NEED

12:30 PM – 1:30 PM EEST

P-305: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS

12:30 PM – 1:30 PM EEST

P-306: Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-307: Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: A post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

12:30 PM – 1:30 PM EEST

P-308: Superiority of daratumumab plus lenalidomide and dexamethasone in first and second relapse in multiple myeloma patients: a real-world single centre retrospective analysis

12:30 PM – 1:30 PM EEST

P-309: ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples

12:30 PM – 1:30 PM EEST

P-310: Treatment Preferences Among Triple-class Exposed Patients With Relapsed/Refractory Multiple Myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a Discrete Choice Experiment

12:30 PM – 1:30 PM EEST

P-311: Survival of patients with relapsed/refractory multiple myeloma receiving palliative therapy with cyclophosphamide/ prednisone: Results in 346 patients from a single institution over the last 50 years

12:30 PM – 1:30 PM EEST

P-312: Impact of the IF system using HYDRASHIFT® on response evaluation for patients under treatment with the IgG-κ monoclonal antibody, isatuximab

12:30 PM – 1:30 PM EEST

P-313: ALLG MM25 (VIBER-M): A Phase Ib/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14)

12:30 PM – 1:30 PM EEST

P-314: Bendamustine Salvage for Relapsed – Refractory Multiple Myeloma: A retrospective analysis of outcomes in heavily pretreated patients.

12:30 PM – 1:30 PM EEST

P-315: Elranatamab exposure-safety analysis in patients with relapsed/refractory multiple myeloma: Analysis from MagnetisMM studies

12:30 PM – 1:30 PM EEST

P-316: NK cell kinetics predict outcome in the multiple treated with elotuzumab, lenalidomide plus dexamethasone (ERd): a subanalysis in Japanese multicenter observation for once monthly ERd study.

12:30 PM – 1:30 PM EEST

P-317: How do patients and providers value innovative multiple myeloma treatments? Evidence from a discrete choice experiment

12:30 PM – 1:30 PM EEST

P-318: The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

12:30 PM – 1:30 PM EEST

P-319: Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA

12:30 PM – 1:30 PM EEST

P-320: Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial

12:30 PM – 1:30 PM EEST

P-321: Real-World Outcomes In Myeloma Patients With t(11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

12:30 PM – 1:30 PM EEST

P-322: Real world outcomes of belantamab mafodotin from the UK and Ireland: updated results.

12:30 PM – 1:30 PM EEST

P-323: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone Versus Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-324: LocoMMotion: A prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

12:30 PM – 1:30 PM EEST

P-325: Standard of Care (SOC) Outcomes in the Last 3 Years in Patients With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): The First Pooled Analysis of LocoMMotion and MoMMent Trials

12:30 PM – 1:30 PM EEST

P-326: Genome-wide CRISPR screen identifies SPOP as a modulator of IMiDs sensitivity in multiple myeloma

12:30 PM – 1:30 PM EEST

P-327: Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-328: Talquetamab vs Real-World Physician’s Choice of Therapy (RWPC): Comparative Efficacy in Patients (pts) With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-329: A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma

12:30 PM – 1:30 PM EEST

P-330: The third-generation genetic engineered mouse model of late-stage multiple myeloma

12:30 PM – 1:30 PM EEST

P-331: Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma

12:30 PM – 1:30 PM EEST

P-492: Pharmacodynamic Effects of Tiragolumab, as Monotherapy and In Combos with Daratumumab and Atezolizumab in Patients with R/R MM: Biomarker Results From a Phase 1a/1b Trial

12:30 PM – 1:30 PM EEST

P-493: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma: an updated clinical study

12:30 PM – 1:30 PM EEST

P-494: Euroflow-based ultrasensitive detection of malignant plasma cells in the bone marrow.

12:30 PM – 1:30 PM EEST

P-496: The influence of the gut microbiome on the development of multiple myeloma.

12:30 PM – 1:30 PM EEST

P-497: Longitudinal single-cell multi-omic profiling of human T cells in newly diagnosed multiple myeloma patients over the course of VRd and autologous stem cell transplant therapy

12:30 PM – 1:30 PM EEST

P-498: Lenalidomide and Pomalidomide Experience: Thrombotic Risk in Hematological Neoplasms

12:30 PM – 1:30 PM EEST

P-499: DETECTION OF BENCE JONES PROTEINURIA BY SERUM FREE LIGHT CHAINS: DELIMITATION OF 24H URINE STUDIES IN PATIENTS WITH MONOCLONAL GAMMOPATHIES.

12:30 PM – 1:30 PM EEST

P-500: MULTIPLE MYELOMA: Do we have scales to assess the risk of Thromboembolic Events (TEV)?

12:30 PM – 1:30 PM EEST

P-501: EHA GUIDELINES FOR THE USE AND REPORTING OF PATIENT-REPORTED OUTCOMES IN MULTIPLE MYELOMA CLINICAL TRIALS

12:30 PM – 1:30 PM EEST

P-502: Evaluating Heterogeneity and Functionality of Bone Marrow Plasma Cells Illuminates Cellular Origins of Myeloma Cells

12:30 PM – 1:30 PM EEST

P-503: The prognosis of different efficacy depth in transplant-eligible newly diagnosed multiple myeloma (MM) patients in China——data of single center

12:30 PM – 1:30 PM EEST

P-504: A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

12:30 PM – 1:30 PM EEST

P-505: Proteomic analysis of CD138+ cells for predicting the response of multiple myeloma patients to commonly used therapeutic regimens

12:30 PM – 1:30 PM EEST

P-506: Single Centre Experience with BCMA-directed Bispecific T Cell Engagers (BiTE) via the Compassionate Access Schemes in Patients with Heavily Pre-Treated Relapsed or Refractory Multiple Myeloma (RRMM)

12:30 PM – 1:30 PM EEST

P-508: A Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma

12:30 PM – 1:30 PM EEST

P-509: Vactosertib, a novel TGF type I receptor kinase inhibitor, improves T-cell fitness:a single-arm, phase 1b trial in relapsed/refractory multiple myeloma